Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, Cejas P, Machado-Pinilla R, Manguan-García C, Sánchez-Pérez I, Nistal M, Moratilla C, de Castro-Carpeño J, Gonzalez-Barón M, Albanell J, Perona R. Cortes-Sempere M, et al. Among authors: albanell j. Cancer Lett. 2009 Dec 28;286(2):206-16. doi: 10.1016/j.canlet.2009.05.029. Epub 2009 Jun 23. Cancer Lett. 2009. PMID: 19553005
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B. Domingo-Domenech J, et al. Among authors: albanell j. Clin Cancer Res. 2006 Sep 15;12(18):5578-86. doi: 10.1158/1078-0432.CCR-05-2767. Clin Cancer Res. 2006. PMID: 17000695 Clinical Trial.
Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin.
Tapia MA, González-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, Gascón P, Rojo F, Perona R, Rovira A, Albanell J. Tapia MA, et al. Among authors: albanell j. Cell Cycle. 2007 Sep 15;6(18):2284-92. doi: 10.4161/cc.6.18.4721. Epub 2007 Jul 10. Cell Cycle. 2007. PMID: 17890907 Free article.
Genetic changes in small cell lung carcinoma.
Arriola E, Cañadas I, Arumí M, Rojo F, Rovira A, Albanell J. Arriola E, et al. Among authors: albanell j. Clin Transl Oncol. 2008 Apr;10(4):189-97. doi: 10.1007/s12094-008-0181-1. Clin Transl Oncol. 2008. PMID: 18411191 Review.
Targeted therapies in breast cancer.
Rojo F, Albanell J, Rovira A, Corominas JM, Manzarbeitia F. Rojo F, et al. Among authors: albanell j. Semin Diagn Pathol. 2008 Nov;25(4):245-61. doi: 10.1053/j.semdp.2008.08.001. Semin Diagn Pathol. 2008. PMID: 19013891 Review.
Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sánchez-Pérez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J. Rojo F, et al. Among authors: albanell j. Clin Cancer Res. 2009 May 15;15(10):3530-9. doi: 10.1158/1078-0432.CCR-08-2070. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417026
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J. Rojo F, et al. Among authors: albanell j. Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371675 Clinical Trial.
264 results